Citations Appearing in 2021

  1. Ayyar, V.S., Song, D., Zheng, S., Carpenter, T. and Heald, D.L., 2021. Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine–Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans. Journal of Pharmacology and Experimental Therapeutics, 379(2), pp.134-146.
  2. Balla, A., Jeong, Y.S., Kim, H.J., Lee, Y.J., Chung, S.J., Chae, Y.J. and Maeng, H.J., 2021. Effects of 1α, 25-dihydroxyvitamin D3 on the pharmacokinetics of procainamide and its metabolite N-acetylprocainamide, organic cation transporter substrates, in rats with PBPK modeling approach. Pharmaceutics, 13(8), p.1133.
  3. Blaser, L.S., Duthaler, U., Bouitbir, J., Leuppi-Taegtmeyer, A.B., Liakoni, E., Dolf, R., Mayr, M., Drewe, J., Krähenbühl, S. and Haschke, M., 2021. Comparative Effects of Metamizole (Dipyrone) and Naproxen on Renal Function and Prostacyclin Synthesis in Salt-Depleted Healthy Subjects-A Randomized Controlled Parallel Group Study. Frontiers in Pharmacology, 12, p.620635.
  4. Bloomingdale, P., Meregalli, C., Pollard, K., Canta, A., Chiorazzi, A., Fumagalli, G., Monza, L., Pozzi, E., Alberti, P., Ballarini, E. and Oggioni, N., 2021. Systems Pharmacology Modeling Identifies a Novel Treatment Strategy for Bortezomib-Induced Neuropathic Pain. Frontiers in Pharmacology, 12.
  5. Bussing, D., Sharma, S., Li, Z., Meyer, L.F. and Shah, D.K., 2021. Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody–Drug Conjugate Exposure in Solid Tumor. The AAPS Journal, 23(3), pp.1-11.
  6. Butterfield-Cowper, J.M., 2021. A Pharmacokinetic-Pharmacodynamic Analysis to Dose Optimize Daptomycin in Vancomycin-Resistant Enterococcus faecium: Is the Answer Fixed Dosing or Lowering Breakpoints?. Annals of Pharmacotherapy, 55(7), pp.846-855.
  7. Caballero Cuenca, U., Kim, S., Eraso Barrio, M.E., Quindós Andrés, G., Vozmediano, V., Schmidt, S. and Jauregizar Albonigamayor, N., 2021. In Vitro Synergistic Interactions of Isavuconazole and Echinocandins against Candida auris.
  8. Caballero, U., Kim, S., Eraso, E., Quindós, G., Vozmediano, V., Schmidt, S. and Jauregizar, N., 2021. In vitro synergistic interactions of isavuconazole and echinocandins against Candida auris. Antibiotics, 10(4), p.355.
  9. Chang, H.P., Kim, S.J. and Shah, D.K., 2021. Whole-body pharmacokinetics of antibody in mice determined using enzyme-linked immunosorbent assay and derivation of tissue interstitial concentrations. Journal of pharmaceutical sciences, 110(1), pp.446-457.
  10. Chen, W., Boras, B., Sung, T., Hu, W., Spilker, M.E. and D’Argenio, D.Z., 2021. A whole‐body circulatory neutrophil model with application to predicting clinical neutropenia from in vitro studies. CPT: pharmacometrics & systems pharmacology, 10(7), pp.671-683.
  11. Chen, W., D’Argenio, D.Z., Sipos, A., Kim, K.J. and Crandall, E.D., 2021. Biokinetic modeling of nanoparticle interactions with lung alveolar epithelial cells: uptake, intracellular processing, and egress. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 320(1), pp.R36-R43.
  12. Chen, X.Y., Qian, F., Wang, Y.Y., Liu, Y., Sun, Y., Zha, W.B., Hao, K., Zhou, F., Wang, G.J. and Zhang, J.W., 2021. Ginsenoside 20 (S)-Rh2 promotes cellular pharmacokinetics and intracellular antibacterial activity of levofloxacin against Staphylococcus aureus through drug efflux inhibition and subcellular stabilization. Acta Pharmacologica Sinica, 42(11), pp.1930-1941.
  13. Darlow, C.A., Docobo-Perez, F., Farrington, N., Johnson, A., McEntee, L., Unsworth, J., Jimenez-Valverde, A., Gastine, S., Kolamunnage-Dona, R., de Costa, R.M. and Ellis, S., 2021. Amikacin combined with fosfomycin for treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance. Antimicrobial Agents and Chemotherapy, 65(7), pp.e00293-21.
  14. Drusano, G.L., Bonomo, R.A., Marshall, S.M., Rojas, L.J., Adams, M.D., Mojica, M.F., Kreiswirth, B.N., Chen, L., Mtchedlidze, N., Bacci, M. and Vicchiarelli, M., 2021. Emergence of Resistance to Ceftazidime-Avibactam in a Pseudomonas aeruginosa Isolate Producing Derepressed bla PDC in a Hollow-Fiber Infection Model. Antimicrobial agents and chemotherapy, 65(6), pp.e00124-21.
  15. Drusano, G.L., Kim, S., Almoslem, M., Schmidt, S., D’Argenio, D.Z., Myrick, J., Duncanson, B., Nole, J., Brown, D., Peloquin, C.A. and Neely, M., 2021. The funnel: a screening technique for identifying optimal two-drug combination chemotherapy regimens. Antimicrobial Agents and Chemotherapy, 65(2), pp.10-1128.
  16. Drusano, G.L., Rogers, S., Brown, D., Peloquin, C.A., Neely, M., Yamada, W., Kim, S., Almoslem, M., Schmidt, S. and Louie, A., 2021. Dose fractionation of moxifloxacin for treatment of tuberculosis: impact of dosing interval and elimination half-life on microbial kill and resistance suppression. Antimicrobial Agents and Chemotherapy, 65(4), pp.e02533-20.
  17. Eales, B.M., Hudson, C.S., Kesisoglou, I., Wang, W., Nikolaou, M. and Tam, V.H., 2021. Experimental Validation of a Mathematical Framework to Simulate Antibiotics with Distinct Half-Lives Concurrently in an In Vitro Model. Antibiotics, 10(10), p.1256.
  18. Felmlee, M.A. and Li, X., 2021. Personalized Medicine: Drug Delivery and Pharmacokinetics. Drug Delivery Approaches: Perspectives from Pharmacokinetics and Pharmacodynamics.
  19. Franco, E.J., Tao, X., Hanrahan, K.C., Zhou, J., Bulitta, J.B. and Brown, A.N., 2021. Combination regimens of favipiravir plus interferon alpha inhibit chikungunya virus replication in clinically relevant human cell lines. Microorganisms, 9(2), p.307.
  20. Gastine, S., Hope, W., Hempel, G., Petraitiene, R., Petraitis, V., Mickiene, D., Bacher, J., Walsh, T.J. and Groll, A.H., 2021. Pharmacodynamics of posaconazole in experimental invasive pulmonary aspergillosis: utility of serum galactomannan as a dynamic endpoint of antifungal efficacy. Antimicrobial Agents and Chemotherapy, 65(2), pp.e01574-20.
  21. Haas, D.W., Podany, A.T., Bao, Y., Swindells, S., Chaisson, R.E., Mwelase, N., Supparatpinyo, K., Mohapi, L., Gupta, A., Benson, C.A. and Baker, P., 2021. Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine. Pharmacogenetics and genomics, 31(1), p.17.
  22. Hanafin, P.O.B., 2021. Teaching an Old Drug New Tricks: Modeling Approaches to Elucidate Polymyxin B Pharmacokinetics, Toxicodynamics, and Pharmacodynamics for Improved Dosing in Critically Ill Patients (Doctoral dissertation, The University of North Carolina at Chapel Hill).
  23. Haschke, M., Blaser, L.S., Duthaler, U.P., BOUITBIR, J., Leuppi-Taegtmeyer, A., Liakoni, E., Dolf, R., Drewe, J. and Krähenbühl, S., 2021. Comparative effects of metamizole (dipyrone) and naproxen on renal function and prostacyclin synthesis in salt‐depleted healthy subjects‐a randomized controlled parallel group study. Frontiers in pharmacology, p.2313.
  24. Hu, S., Lu, Y., Tura, A., Pacini, G. and D’Argenio, D.Z., 2021. An analysis of glucose effectiveness in subjects with or without type 2 diabetes via hierarchical modeling. Frontiers in endocrinology, 12, p.641713.
  25. Ilić, T., Pantelić, I. and Savić, S., 2021. The implications of regulatory framework for topical semisolid drug products: From critical quality and performance attributes towards establishing bioequivalence. Pharmaceutics, 13(5), p.710.
  26. Jacobsson, S., Golparian, D., Oxelbark, J., Alirol, E., Franceschi, F., Gustafsson, T.N., Brown, D., Louie, A., Drusano, G. and Unemo, M., 2021. Pharmacodynamic evaluation of dosing, bacterial kill, and resistance suppression for zoliflodacin against Neisseria gonorrhoeae in a dynamic hollow fiber infection model. Frontiers in Pharmacology, 12, p.682135.
  27. Jankowska, A., Satała, G., Świerczek, A., Pociecha, K., Partyka, A., Jastrzębska-Więsek, M., Głuch-Lutwin, M., Bojarski, A.J., Wyska, E. and Chłoń-Rzepa, G., 2021. A new class of 5-HT1A receptor antagonists with procognitive and antidepressant properties. Future Medicinal Chemistry, 13(18), pp.1497-1514.
  28. Jeong, Y.S. and Jusko, W.J., 2021. Meta-assessment of metformin absorption and disposition pharmacokinetics in nine species. Pharmaceuticals, 14(6), p.545.
  29. Jorgensen, S.C., Dersch-Mills, D., Timberlake, K., Stewart, J.J., Gin, A., Dresser, L.D. and Dalton, B.R., 2021. AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics. Journal of Antimicrobial Chemotherapy, 76(9), pp.2237-2251.
  30. Kim, Y.H., Kim, K.J., D’Argenio, D.Z. and Crandall, E.D., 2021. Characteristics of Passive Solute Transport across Primary Rat Alveolar Epithelial Cell Monolayers. Membranes, 11(5), p.331.
  31. Kumar, A., Kini, S.G. and Rathi, E., 2021. A recent appraisal of artificial intelligence and in silico ADMET prediction in the early stages of drug discovery. Mini Reviews in Medicinal Chemistry, 21(18), pp.2788-2800.
  32. Kwak, J.H., Kim, Y., Staatz, C.E. and Baek, I.H., 2021. Oral bioavailability and pharmacokinetics of esculetin following intravenous and oral administration in rats. Xenobiotica, 51(7), pp.811-817.
  33. Li, Z., Yu, X., Li, Y., Verma, A., Chang, H.P. and Shah, D.K., 2021. A two-pore physiologically based pharmacokinetic model to predict subcutaneously administered different-size antibody/antibody fragments. The AAPS journal, 23(3), pp.1-13.
  34. Liu, Q., Bi, G., Chen, G., Guo, X., Tu, S., Tong, X., Xu, M., Liu, M., Wang, B., Jiang, H. and Wang, J., 2021. Time-Dependent Distribution of Hydroxychloroquine in Cynomolgus Macaques Using Population Pharmacokinetic Modeling Method. Frontiers in Pharmacology, 11, p.602880.
  35. Liu, X. and Jusko, W.J., 2021. Physiologically based pharmacokinetics of lysosomotropic chloroquine in rat and human. Journal of Pharmacology and Experimental Therapeutics, 376(2), pp.261-272.
  36. Liu, X., Anissimov, Y.G., Grice, J.E., Cheruvu, H.S., Ghosh, P., Raney, S.G., Maibach, H.I. and Roberts, M.S., 2021. Relating transdermal delivery plasma pharmacokinetics with in vitro permeation test (IVPT) findings using diffusion and compartment-in-series models. Journal of Controlled Release, 334, pp.37-51.
  37. Lv, C., Yuan, D. and Cao, Y., 2021. Downregulation of Interferon-γ Receptor Expression Endows Resistance to Anti–Programmed Death Protein 1 Therapy in Colorectal Cancer. Journal of Pharmacology and Experimental Therapeutics, 376(1), pp.21-28.
  38. Monine, M., Norris, D., Wang, Y. and Nestorov, I., 2021. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration. Journal of Pharmacokinetics and Pharmacodynamics, 48(5), pp.639-654.
  39. Nair, S., Davis, A., Campagne, O., Schuetz, J.D. and Stewart, C.F., 2021. Development and validation of an LC-MS/MS method to quantify the bromodomain and extra-terminal (BET) inhibitor JQ1 in mouse plasma and brain microdialysate: Application to cerebral microdialysis study. Journal of Pharmaceutical and Biomedical Analysis, 204, p.114274.
  40. Nanavati, C. and Mager, D.E., 2021. Network-Based Systems Analysis Explains Sequence-Dependent Synergism of Bortezomib and Vorinostat in Multiple Myeloma. The AAPS Journal, 23(5), pp.1-12.
  41. Nauwelaerts, N., Deferm, N., Smits, A., Bernardini, C., Lammens, B., Gandia, P., Panchaud, A., Nordeng, H., Bacci, M.L., Forni, M. and Ventrella, D., 2021. A comprehensive review on non-clinical methods to study transfer of medication into breast milk–A contribution from the ConcePTION project. Biomedicine & pharmacotherapy, 136, p.111038.
  42. Neely, M.N. and Vinks, A.A., 2021. Roger W. Jelliffe, MD, FCP, FAAPS: A World Leader in Population Pharmacokinetic and Pharmacodynamic Modeling and Model‐Based Target Controlled Individualized Dosing. Clinical Pharmacology & Therapeutics, 109(1), pp.22-24.
  43. Podany, A.T., Leon-Cruz, J., Hakim, J., Supparatpinyo, K., Omoz-Oarhe, A., Langat, D., Mwelase, N., Kanyama, C., Gupta, A., Benson, C.A. and Chaisson, R.E., 2021. Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. Journal of Antimicrobial Chemotherapy, 76(3), pp.718-721.
  44. Rodriguez-Urretavizcaya, B., Pascual, N., Pastells, C., Martin-Gomez, M.T., Vilaplana, L. and Marco, M.P., 2021. Diagnosis and Stratification of Pseudomonas aeruginosa Infected Patients by Immunochemical Quantitative Determination of Pyocyanin From Clinical Bacterial Isolates. Frontiers in cellular and infection microbiology, 11.
  45. Rong, Y., Jun, H. and Kiang, T.K., 2021. Population pharmacokinetics of mycophenolic acid in paediatric patients. British Journal of Clinical Pharmacology, 87(4), pp.1730-1757.
  46. Rubino, C.M., Onufrak, N.J., van Ingen, J., Griffith, D.E., Bhavnani, S.M., Yuen, D.W., Mange, K.C. and Winthrop, K.L., 2021. Population pharmacokinetic evaluation of amikacin liposome inhalation suspension in patients with treatment-refractory nontuberculous mycobacterial lung disease. European journal of drug metabolism and pharmacokinetics, 46(2), pp.277-287.
  47. Ručilová, V., Świerczek, A., Vanda, D., Funk, P., Lemrová, B., Gawalska, A., Bucki, A., Nowak, B., Zadrożna, M., Pociecha, K. and Soural, M., 2021. New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases. European Journal of Medicinal Chemistry, 209, p.112854.
  48. Shin, B.S. and Kang, W., 2021. Pharmacokinetics of panduratin A following oral administration of a Boesenbergia. JOURNAL OF FOOD AND DRUG ANALYSIS, 20, p.1e8.
  49. Smith, N.M., Chan, A., Wilkinson, L.A., Chua, H.C., Nguyen, T.D., de Souza, H., Shah, A.P., D’Argenio, D.Z. and Mergenhagen, K.A., 2021. Open‐source maximum a posteriori‐bayesian dosing AdDS to current therapeutic drug monitoring: Adapting to the era of individualized therapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 41(11), pp.953-963.
  50. Song, D. and Jusko, W.J., 2021. Across‐species meta‐analysis of dexamethasone pharmacokinetics utilizing allometric and scaling modeling approaches. Biopharmaceutics & drug disposition, 42(5), pp.191-203.
  51. Srivastava, S., Chapagain, M., van Zyl, J., Deshpande, D. and Gumbo, T., 2021. Potency of vancomycin against Mycobacterium tuberculosis in the hollow fiber system model. Journal of Global Antimicrobial Resistance, 24, pp.403-410.
  52. Srivastava, S., Cirrincione, K.N., Deshpande, D. and Gumbo, T., 2021. Tedizolid, faropenem, and moxifloxacin combination with potential activity against nonreplicating Mycobacterium tuberculosis. Frontiers in Pharmacology, 11, p.616294.
  53. Srivastava, S., Gumbo, T. and Thomas, T., 2021. Repurposing cefazolin-avibactam for the treatment of drug resistant Mycobacterium tuberculosis. Frontiers in Pharmacology, 12, p.776969.
  54. Srivastava, S., Thomas, T., Howe, D., Malinga, L., Raj, P., Alffenaar, J.W. and Gumbo, T., 2021. Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis. Frontiers in pharmacology, 12, p.677005.
  55. Stott, K.E., Le, T., Nguyen, T., Whalley, S., Unsworth, J., Ly, V.T., Kolamunnage-Dona, R. and Hope, W., 2021. Population pharmacokinetics and pharmacodynamics of itraconazole for disseminated infection caused by Talaromyces marneffei. Antimicrobial agents and chemotherapy, 65(11), pp.e00636-21.
  56. Świerczek, A., Plutecka, H., Ślusarczyk, M., Chłoń-Rzepa, G. and Wyska, E., 2021. PK/PD modeling of the PDE7 inhibitor—GRMS-55 in a mouse model of autoimmune hepatitis. Pharmaceutics, 13(5), p.597.
  57. Tam, V.H., Abodakpi, H., Wang, W., Ledesma, K.R., Merlau, P.R., Chan, K., Altman, R., Tran, T.T., Nikolaou, M. and Sofjan, A.K., 2021. Optimizing pharmacokinetics/pharmacodynamics of β-lactam/β-lactamase inhibitor combinations against high inocula of ESBL-producing bacteria. Journal of Antimicrobial Chemotherapy, 76(1), pp.179-183.
  58. Thomas, J.S., El-Khoueiry, A.B., Maurer, B.J., Groshen, S., Pinski, J.K., Cobos, E., Gandara, D.R., Lenz, H.J., Kang, M.H., Reynolds, C.P. and Newman, E.M., 2021. A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors. Cancer Chemotherapy and Pharmacology, 87(4), pp.525-532.
  59. Touw, D.J. and van den Anker, J.N., 2021. Therapeutic drug monitoring of antimicrobial drugs in neonates. An opinion paper. Therapeutic Drug Monitoring.
  60. Upton, R.N., Hopkins, A.M., Abuhelwa, A.Y., Hughes, J.H. and Foster, D.J., 2021. Physiologically Based Models: Techniques and Applications to Drug Delivery. Drug Delivery Approaches: Perspectives from Pharmacokinetics and Pharmacodynamics.
  61. Weiss, M. and Siegmund, W., 2021. Unusual Distribution Kinetics of Gadoxetate in Healthy Human Subjects Genotyped for OATP1B1: Application of Population Analysis and a Minimal Physiological‐Based Pharmacokinetic Model. The Journal of Clinical Pharmacology, 61(4), pp.506-514.
  62. Wójcik-Pszczoła, K., Jankowska, A., Ślusarczyk, M., Jakieła, B., Plutecka, H., Pociecha, K., Świerczek, A., Popiół, J., Koczurkiewicz-Adamczyk, P., Wyska, E. and Pękala, E., 2021. Synthesis and in vitro evaluation of anti-inflammatory, antioxidant, and anti-fibrotic effects of new 8-aminopurine-2, 6-dione-based phosphodiesterase inhibitors as promising anti-asthmatic agents. Bioorganic Chemistry, 117, p.105409.
  63. Won, J., Noh, K., Hwang, J.K., Shin, B.S. and Kang, W., 2021. Pharmacokinetics of panduratin A following oral administration of a Boesenbergia pandurata extract to rats. Journal of Food & Drug Analysis, 29(4).
  64. Xiang, H., Chan, A.G., Ahene, A., Bellovin, D.I., Deng, R., Hsu, A.W., Jeffry, U., Palencia, S., Powers, J., Zanghi, J. and Collins, H., 2021, January. Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer. In Mabs (Vol. 13, No. 1, p. 1981202). Taylor & Francis.
  65. ZHAO Lu-lu, MIAO Xin, WANG Sheng-nan, GAO Yuan, GU Chao, LI Gang. Study on integrated TK-TD model of Radix Aconiti Kusnezoffii and Fructus Chebulae. China Journal of Traditional Chinese Medicine and Pharmacy,2021(2).